Education
FDA Approves Wegovy Weight-Loss Pill: What to Know About Oral Semaglutide
This episode explains the first FDA-approved GLP-1 weight-loss drug in pill form: a once-daily oral semaglutide tablet (Wegovy pill) approved on December 22, 2025, with a U.S. launch in early January 2026. It clarifies that Rybelsus is also oral semaglutide but is only approved for type 2 diabetes, making Wegovy the first oral GLP-1 specifically approved for chronic weight management. Results from the 71-week OASIS 4 trial showed average weight loss of 13.6% at a 25 mg dose versus 2.2% with placebo, with adherent patients closer to 16.6%. The script highlights strict dosing requirements (empty stomach, ≤4 oz water, wait 30 minutes), similar nausea side effects to injections, expected similar pricing, and ongoing insurance and adherence hurdles while noting improved access for those avoiding injections.
00:00 Oral Wegovy Arrives
00:35 What Makes It New
00:53 OASIS 4 Results
01:33 How to Take It
01:58 Who Benefits Most
02:28 Caveats and Costs
02:49 Wrap Up